{"id":525912,"date":"2021-08-10T08:04:27","date_gmt":"2021-08-10T12:04:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/"},"modified":"2021-08-10T08:04:27","modified_gmt":"2021-08-10T12:04:27","slug":"cue-biopharma-to-host-business-update-call-and-webcast","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/","title":{"rendered":"Cue Biopharma\u00a0to Host Business Update Call and Webcast"},"content":{"rendered":"
\n

CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Cue Biopharma, Inc.<\/a> (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\u2019s body, announced today it will host a conference call and webcast to provide a business update on\u00a0Tuesday, August 17, 2021\u00a0at\u00a04:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company\u2019s\u00a0website<\/a>.<\/p>\n

Members of the\u00a0Cue Biopharma\u00a0executive management team will provide a clinical update from the Company\u2019s clinical trials with CUE-101, its lead and representative IL-2 based drug product candidate from the CUE-100 series. CUE-101 is currently in a Phase 1b clinical trial for the treatment of HPV+ recurrent\/metastatic head and neck squamous cell carcinoma. The discussion will focus on data updates from the Phase 1a\/b monotherapy dose escalation and expansion trials, the combination trial evaluating CUE-101 front line with Merck\u2019s pembrolizumab (KEYTRUDA\u00ae<\/sup>) and the upcoming neoadjuvant trial. Management will also provide an update on the Company\u2019s technology platform developments and pipeline development progress from the IL-2 based CUE-100 series including CUE-102, as well as updates on its strategic objectives and anticipated milestones.<\/p>\n\n\n\n\n\n\n\n\n
\n Webcast Details<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Tuesday, August 17, 2021 at\u00a04:30 p.m. EDT<\/strong>\u00a0\u00a0<\/td>\n<\/tr>\n
\n Investors:<\/strong>\n <\/td>\n877-407-9208<\/td>\n<\/tr>\n
\n International:\u00a0<\/strong>\n <\/td>\n201-493-6784<\/td>\n<\/tr>\n
\n Conference ID:\u00a0<\/strong>\n <\/td>\n13721829<\/td>\n<\/tr>\n
\n Webcast:\u00a0\u00a0<\/strong>
\n http:\/\/public.viavid.com\/index.php?id=145891<\/a>\n <\/td>\n<\/tr>\n<\/table>\n

\n About\u00a0Cue Biopharma<\/strong>
\n
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient\u2019s body to transform the treatment of cancer, infectious disease and autoimmune disease. The company\u2019s proprietary Immuno-STAT\u2122\u00a0(Selective Targeting and Alteration of T cells)<\/em> platform is designed to harness the body\u2019s intrinsic immune system without the need for ex vivo manipulation.<\/p>\n

Headquartered in Cambridge, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.<\/p>\n

For more information, visit\u00a0www.cuebiopharma.com<\/a> and follow us on Twitter at https:\/\/twitter.com\/CueBiopharma<\/a>.<\/p>\n

\n Investor Contact<\/strong>
\n
George B. Zavoico, Ph.D.
VP, Investor Relations & Corporate Development
Cue Biopharma, Inc.
gzavoico@cuebio.com<\/a><\/p>\n

\n Media Contact<\/strong>
\n
Darren Opland, Ph.D.
LifeSci Communications
darren@lifescicomms.com<\/a><\/p>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\u2019s body, announced today it will host a conference call and webcast to provide a business update on\u00a0Tuesday, August 17, 2021\u00a0at\u00a04:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company\u2019s\u00a0website. Members of the\u00a0Cue Biopharma\u00a0executive management team will provide a clinical update from the Company\u2019s clinical trials with CUE-101, its lead and representative IL-2 based drug product candidate from the CUE-100 series. CUE-101 is currently in a Phase 1b clinical trial for the treatment of HPV+ recurrent\/metastatic head and … <\/p>\n

Continue reading “Cue Biopharma\u00a0to Host Business Update Call and Webcast”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-525912","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCue Biopharma\u00a0to Host Business Update Call and Webcast - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cue Biopharma\u00a0to Host Business Update Call and Webcast - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\u2019s body, announced today it will host a conference call and webcast to provide a business update on\u00a0Tuesday, August 17, 2021\u00a0at\u00a04:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company\u2019s\u00a0website. Members of the\u00a0Cue Biopharma\u00a0executive management team will provide a clinical update from the Company\u2019s clinical trials with CUE-101, its lead and representative IL-2 based drug product candidate from the CUE-100 series. CUE-101 is currently in a Phase 1b clinical trial for the treatment of HPV+ recurrent\/metastatic head and … Continue reading "Cue Biopharma\u00a0to Host Business Update Call and Webcast"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-10T12:04:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzIyMSM0MzE1NjM3IzIwOTI2OTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cue Biopharma\u00a0to Host Business Update Call and Webcast\",\"datePublished\":\"2021-08-10T12:04:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast\\\/\"},\"wordCount\":389,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NzIyMSM0MzE1NjM3IzIwOTI2OTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast\\\/\",\"name\":\"Cue Biopharma\u00a0to Host Business Update Call and Webcast - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NzIyMSM0MzE1NjM3IzIwOTI2OTI=\",\"datePublished\":\"2021-08-10T12:04:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NzIyMSM0MzE1NjM3IzIwOTI2OTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NzIyMSM0MzE1NjM3IzIwOTI2OTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cue Biopharma\u00a0to Host Business Update Call and Webcast\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cue Biopharma\u00a0to Host Business Update Call and Webcast - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/","og_locale":"en_US","og_type":"article","og_title":"Cue Biopharma\u00a0to Host Business Update Call and Webcast - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\u2019s body, announced today it will host a conference call and webcast to provide a business update on\u00a0Tuesday, August 17, 2021\u00a0at\u00a04:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company\u2019s\u00a0website. Members of the\u00a0Cue Biopharma\u00a0executive management team will provide a clinical update from the Company\u2019s clinical trials with CUE-101, its lead and representative IL-2 based drug product candidate from the CUE-100 series. CUE-101 is currently in a Phase 1b clinical trial for the treatment of HPV+ recurrent\/metastatic head and … Continue reading \"Cue Biopharma\u00a0to Host Business Update Call and Webcast\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-10T12:04:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzIyMSM0MzE1NjM3IzIwOTI2OTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cue Biopharma\u00a0to Host Business Update Call and Webcast","datePublished":"2021-08-10T12:04:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/"},"wordCount":389,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzIyMSM0MzE1NjM3IzIwOTI2OTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/","name":"Cue Biopharma\u00a0to Host Business Update Call and Webcast - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzIyMSM0MzE1NjM3IzIwOTI2OTI=","datePublished":"2021-08-10T12:04:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzIyMSM0MzE1NjM3IzIwOTI2OTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzIyMSM0MzE1NjM3IzIwOTI2OTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cue Biopharma\u00a0to Host Business Update Call and Webcast"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/525912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=525912"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/525912\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=525912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=525912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=525912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}